Syngene, Endo tie up to develop
Syngene International, a subsidiary of Biocon, has entered into a
discovery and development collaboration with Endo Pharmaceuticals, US,
to develop novel biological therapeutic molecules against cancer. Under
the terms of the agreement, Endo will retain all rights to the
molecules developed, while Syngene International will receive research
fees, milestone payments and success fees from Endo.
Speaking on the development, Kiran Mazumdar-Shaw, CMD, Biocon Group,
said, “We are very pleased to enter into this collaboration with Endo
Pharmaceuticals as it showcases Syngene as an integrated custom
research service provider. This agreement is also very significant
considering the fact that it is for the first time in India that such a
deal has been signed involving the discovery of a biological
“We look forward to collaborating with Syngene in our efforts to
discover novel treatments for oncology and deliver solutions to
patients and providers. This collaboration that marks our entry into
the biologics discovery space, is consistent with our strategy of
building Endo's pipeline using a virtual discovery approach, in
conjunction with our in-licensing efforts,” concludes Sandeep Gupta,
senior vice president of drug discovery and early development at Endo.
Bilcare research opens new unit
Bilcare Global Clinical Supplies has opened its second unit in The
Elvicta Industrial Estate, Crickhowell, Wales, UK. The new unit will
add 30,000 sq.ft. and double the company's European capacity to
package, store and distribute clinical supplies in ambient,
refrigerated and frozen conditions.
Bilcare – a global company headquartered in India – established its
Crickhowell site in 2006 when it purchased DHP. The Bilcare Global
Clinical Supplies facility at Crickhowell is contributing to a nascent
pharmaceutical 'cluster' of companies in UK.
Mohan Bhandari, chairman and MD of Bilcare Limited, said, “With the
drug discovery program leading to potential new drugs becoming more
complex, the need to clinically test drug efficacy and safety in
diverse population groups across multiple geographic regions is
becoming a crucial necessity. This necessity has led Bilcare to expand
and open new facilities in the US, Europe and Asia.”
In conjunction with the expansion, Bilcare Research specializes in
primary packaging for pharmaceutical products and security technology
such as nonClonable. Based on modular architecture, nonClonable
enhances customer safety, improves supply chain efficiency, reduces
inventory levels, and improves customer relationship management.
VLife to develop technology for
VLife Sciences Technologies has signed a contract with National Center
for Biological Sciences (NCBS), Bangalore for developing a specialized
modeling and simulation technology in the area of protein-protein
interactions. The project is undertaken jointly by NCBS, Stanford
University and Technical University of Denmark.
This project involves studying coiled coil interactions in proteins
which will provide opportunity to encounter and study hitherto
uncharacterized myosins, key players in the dynamic organization of
cellular components. With this project, VLife has reinforced its
ability to execute scientific computational work, which has made it a
partner with institutes across the world.
GVK opens clinical pharmacology
unit in Gujarat
GVK Biosciences (GVK BIO) has commissioned its new clinical
pharmacology unit (CPU) in Ahmedabad. The new unit adds 110 beds to GVK
BIO's existing capacity of 144 beds. The new CPU will conduct a variety
of studies in healthy volunteers.
Ahmedabad was the most preferred and logical destination for expansion
considering the volunteer pool accessibility and proximity to about 10
CROs and leading pharma companies. With three clinical wards and 110
beds, the unit is designed to suit all regulatory requirements. It also
has special housing facilities for female volunteers. The unit include
access to special population like young women, post-menopausal women,
diseased population and access to about 12,000 healthy volunteers.
GVK BIO's CPU is a top service provider of bioequivalence studies to
generic pharma companies globally. The CPU unit, operational from 2004
in Hyderabad, has undergone several international audits, inspections
and has key accreditations to its credit including the USFDA, DCG(I),
ANVISA (Brazil), AFSSAPS (France), WHO and the Ministry of Health,
Turkey. In addition to the healthy volunteer population, the Ahmedabad
facility gives access to diseased population in psychiatry, metabolism,
cardiovascular and neurology.
“The facility's new CPU has been audited by the DCGI and we have
initiated our first study at the Ahmedabad facility,” said Manni
Kantipudi, president, GVK Biosciences.